Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.

Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT.

BJU Int. 2007 Apr;99(4):786-93. Epub 2007 Jan 12.

2.

Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Shukla-Dave A, Hricak H, Akin O, Yu C, Zakian KL, Udo K, Scardino PT, Eastham J, Kattan MW.

BJU Int. 2012 May;109(9):1315-22. doi: 10.1111/j.1464-410X.2011.10612.x. Epub 2011 Sep 20.

3.

Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.

Bianco FJ Jr, Mallah KN, Korets R, Hricak H, Scardino PT, Kattan MW.

Urology. 2007 Feb;69(2):343-6.

PMID:
17320675
4.

Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse.

Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL.

Clin Prostate Cancer. 2004 Dec;3(3):174-81.

PMID:
15636684
5.

Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.

Goris Gbenou MC, Peltier A, Addla SK, Lemort M, Bollens R, Larsimont D, Roumeguère T, Schulman CC, van Velthoven R.

Urol Int. 2012;88(1):12-7. doi: 10.1159/000331909. Epub 2011 Oct 15.

PMID:
22004874
6.

Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.

Poulakis V, Witzsch U, de Vries R, Emmerlich V, Meves M, Altmannsberger HM, Becht E.

Urology. 2004 Sep;64(3):516-21.

PMID:
15351582
7.

Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.

Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.

BJU Int. 2008 Aug;102(4):452-8. doi: 10.1111/j.1464-410X.2008.07633.x. Epub 2008 May 12.

9.

Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.

Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, Dattagupta S, Thulkar S.

Urology. 2008 Oct;72(4):859-63. doi: 10.1016/j.urology.2008.01.014. Epub 2008 Mar 10.

PMID:
18329078
10.

Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, Passariello R, Di Silverio F, Gentile V.

Eur Urol. 2008 Sep;54(3):589-600. doi: 10.1016/j.eururo.2007.12.034. Epub 2007 Dec 31.

PMID:
18226441
11.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.

J Urol. 2005 Mar;173(3):752-6.

PMID:
15711262
12.

Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate.

Fütterer JJ, Scheenen TW, Heijmink SW, Huisman HJ, Hulsbergen-Van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO.

Invest Radiol. 2007 Feb;42(2):116-22.

PMID:
17220729
13.

The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.

Lawrentschuk N, Fleshner N.

BJU Int. 2009 Mar;103(6):730-3. doi: 10.1111/j.1464-410X.2008.08205.x. Epub 2009 Jan 14. Review.

14.

Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.

Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM, Joe BN, Kurhanewicz J.

AJR Am J Roentgenol. 2007 Mar;188(3):812-6.

PMID:
17312072
15.
16.

Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men.

Egawa S, Suyama K, Matsumoto K, Satoh T, Uchida T, Kuwao S, Koshiba K.

Urology. 1998 Sep;52(3):433-40.

PMID:
9730456
17.

Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer.

Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, Scardino PT.

AJR Am J Roentgenol. 2006 Mar;186(3):743-8.

PMID:
16498101
18.

Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.

Nishimoto K, Nakashima J, Hashiguchi A, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M, Murai M.

Int J Urol. 2008 Jun;15(6):520-3. doi: 10.1111/j.1442-2042.2008.02042.x. Epub 2008 Apr 15.

19.

After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.

Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H.

BJU Int. 2008 Jan;101(2):170-4. doi: 10.1111/j.1464-410X.2007.07270.x.

20.

Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.

Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barceló J, Ferrer J, Albanell J.

AJR Am J Roentgenol. 2011 Jun;196(6):W715-22. doi: 10.2214/AJR.10.5700.

PMID:
21606259

Supplemental Content

Support Center